{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:25:34Z","timestamp":1790760334128,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jphs.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T18:54:23Z","timestamp":1680202463000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"152","author":[{"given":"Chen","family":"Xun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jphs.2023.03.004_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"10.1016\/j.jphs.2023.03.004_bib2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/annonc\/mdy510","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Vogel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jphs.2023.03.004_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17beta-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.jphs.2023.03.004_bib4","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.18632\/aging.202380","article-title":"Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging"},{"issue":"5","key":"10.1016\/j.jphs.2023.03.004_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","article-title":"A\u00a0positive feedback loop of AKR1C3-mediated activation of NF-\u03baB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma","volume":"81","author":"Zhou","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2023.03.004_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2015.05.010","article-title":"Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)","volume":"153","author":"Penning","year":"2015","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.jphs.2023.03.004_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-09-3237","article-title":"The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3","volume":"70","author":"Guise","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.jphs.2023.03.004_bib8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2020.1728746","article-title":"An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.jphs.2023.03.004_bib9","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.jphs.2023.03.004_bib10","article-title":"The in-vitro antitumor effects of AST-3424 monotherapy and combination therapy with oxaliplatin or 5-fluorouracil in primary liver cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jphs.2023.03.004_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153184","article-title":"beta-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323\/Cbl-b\/EGFR pathway","volume":"69","author":"Deng","year":"2020","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.jphs.2023.03.004_bib12","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1111\/jcmm.13605","article-title":"LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363","volume":"22","author":"Huang","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.jphs.2023.03.004_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102610","article-title":"The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma","volume":"51","author":"Xia","year":"2020","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.jphs.2023.03.004_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4103\/jcrt.JCRT_400_19","article-title":"Apatinib for hepatocellular carcinoma","volume":"15","author":"Ni","year":"2019","journal-title":"J\u00a0Cancer Res Therapeut"},{"issue":"11","key":"10.1016\/j.jphs.2023.03.004_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.jphs.2023.03.004_bib16","first-page":"3269","article-title":"Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment","volume":"268","author":"Kang","year":"2021","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jphs.2023.03.004_bib17","article-title":"Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma","volume":"208","author":"Liu","year":"2019","journal-title":"J\u00a0Proteonomics"},{"key":"10.1016\/j.jphs.2023.03.004_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.568759","article-title":"Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond","volume":"11","author":"Lee","year":"2020","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jphs.2023.03.004_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mc.20659","article-title":"Sp1 upregulates the four and half lim 2 (FHL2) expression in gastrointestinal cancers through transcription regulation","volume":"49","author":"Guo","year":"2010","journal-title":"Mol Carcinog"},{"issue":"2","key":"10.1016\/j.jphs.2023.03.004_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00666038","article-title":"Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors","volume":"36","author":"Weidner","year":"1995","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.jphs.2023.03.004_bib21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1158\/0008-5472.CAN-15-1233","article-title":"Penfluridol: an antipsychotic agent suppresses metastatic tumor growth in triple-negative breast cancer by inhibiting integrin signaling Axis","volume":"76","author":"Ranjan","year":"2016","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jphs.2023.03.004_bib22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1634\/theoncologist.2014-0190","article-title":"Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study","volume":"19","author":"Qin","year":"2014","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jphs.2023.03.004_bib23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jphs.2023.03.004_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jphs.2023.03.004_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10088","key":"10.1016\/j.jphs.2023.03.004_bib26","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jphs.2023.03.004_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jphs.2023.03.004_bib28","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"issue":"44","key":"10.1016\/j.jphs.2023.03.004_bib29","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017813","article-title":"Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis","volume":"98","author":"Yao","year":"2019","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.jphs.2023.03.004_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.semdp.2016.12.011","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"34","author":"Hartke","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1016\/j.jphs.2023.03.004_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2016.04.009","article-title":"Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer","volume":"65","author":"Bissig-Choisat","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jphs.2023.03.004_bib32","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.jphs.2023.03.004_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082431","article-title":"Patient-derived xenograft models for endometrial cancer research","volume":"19","author":"Moiola","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jphs.2023.03.004_bib34","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.canlet.2019.10.015","article-title":"Targeting USP9x\/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid","volume":"469","author":"Chen","year":"2020","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.jphs.2023.03.004_bib35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.31298","article-title":"Establishment of a patient-derived xenograft tumor from hepatitis C-associated liver cancer and evaluation of imatinib treatment efficacy","volume":"72","author":"Nazzal","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jphs.2023.03.004_bib36","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1021\/cr9800199","article-title":"DNA cross-linking agents as antitumor drugs","volume":"98","author":"Rajski","year":"1998","journal-title":"Chem Rev"},{"issue":"10","key":"10.1016\/j.jphs.2023.03.004_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2018.07.005","article-title":"AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling","volume":"36","author":"Wang","year":"2018","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.jphs.2023.03.004_bib38","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","article-title":"AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia","volume":"126","author":"Moradi Manesh","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jphs.2023.03.004_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3324\/haematol.2014.118455","article-title":"Phase I\/II study of the hypoxia-activated prodrug PR104 in refractory\/relapsed acute myeloid leukemia and acute lymphoblastic leukemia","volume":"100","author":"Konopleva","year":"2015","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.jphs.2023.03.004_bib40","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jphs.2023.03.004_bib41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"s","key":"10.1016\/j.jphs.2023.03.004_bib42","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2019.37.15_suppl.4074","article-title":"A\u00a0phase\u2161study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer","volume":"37","author":"Qin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jphs.2023.03.004_bib43","article-title":"Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with unresectable hepatocellular carcinoma (HAIROX): a phase II, single-arm, prospective study","volume":"38","author":"S","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.jphs.2023.03.004_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4083","article-title":"A\u00a0phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study)","volume":"39","author":"He","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2023.03.004_bib45","series-title":"OBI-3424, an AKR1C3-activated prodrug, exhibits in\u00a0vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death","year":"2022"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132300018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134786132300018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:03:06Z","timestamp":1761163386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134786132300018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S134786132300018X"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2023.03.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel AKR1C3 specific prodrug AST-3424 and its combination therapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}